Base de dados : MEDLINE
Pesquisa : C04.557.450.565.465 [Categoria DeCS]
Referências encontradas : 1349 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 135 ir para página                         

  1 / 1349 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779084
[Au] Autor:Bonadonna P; Bonifacio M; Zanotti R
[Ad] Endereço:Allergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
[Ti] Título:Mast Cell Disorders In Drug Hypersensitivity.
[So] Source:Curr Pharm Des;22(45):6862-6869, 2016.
[Is] ISSN:1873-4286
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Mastocytosis is a clonal disease characterized by proliferation and accumulation of mast cells (MC) in different tissues, preferentially skin and bone marrow, leading to a wide variety of clinical manifestations, mainly caused by the inappropriate release of MC mediators. As a consequence, patients with mastocytosis may experience symptoms due to massive MC activation and release of mediators. Anaphylaxis is the most frequent manifestation of this phenomenon. Drugs are possible triggers of anaphylaxis in patients with mastocytosis, even though the association between mastocytosis and drug anaphylaxis does not appear to be as strong as anaphylaxis after hymenoptera sting; nevertheless, MC disorders might be ruled out in cases of severe systemic reactions to drugs. Moreover, the risk of perioperative anaphylaxis in adults appears high, mainly in patients with indolent systemic mastocytosis regardless of skin involvement. Such risk is probably lower in patients who have never experienced anaphylaxis and/or have tolerated previous general anaesthesia. However, data published about drug anaphylaxis in patients with MC disorders are scanty and currently it is not possible to provide clear recommendations.
[Mh] Termos MeSH primário: Anafilaxia/imunologia
Hipersensibilidade a Drogas/imunologia
Mastócitos/imunologia
Mastócitos/patologia
Mastocitose/patologia
[Mh] Termos MeSH secundário: Anafilaxia/diagnóstico
Anafilaxia/epidemiologia
Hipersensibilidade a Drogas/diagnóstico
Hipersensibilidade a Drogas/epidemiologia
Seres Humanos
Mastócitos/efeitos dos fármacos
Mastocitose/diagnóstico
Mastocitose/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.2174/1381612822666160928121857


  2 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28807108
[Au] Autor:Sadeghian A; Rouhana H; Oswald-Stumpf B; Boh E
[Ad] Endereço:Department of Dermatology, Tulane University, New Orleans, Louisiana.
[Ti] Título:Etiologies and management of cutaneous flushing: Malignant causes.
[So] Source:J Am Acad Dermatol;77(3):405-414, 2017 Sep.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The second article in this 2-part continuing medical education series reviews the following malignant causes of flushing: mastocytosis, medullary thyroid carcinoma, pheochromocytoma, carcinoid tumors, gastroenteropancreatic neuroendocrine tumors, bronchogenic carcinoma, vasointestinal polypeptide secreting tumors, and renal cell carcinoma. The information provided will allow physicians to better distinguish patients who have worrisome presentations that require a more thorough investigation. Appropriate diagnostic workup and treatment options for these malignancies are reviewed.
[Mh] Termos MeSH primário: Rubor/etiologia
Neoplasias/complicações
[Mh] Termos MeSH secundário: Neoplasias das Glândulas Suprarrenais/complicações
Carcinoma Neuroendócrino/complicações
Carcinoma de Células Renais/complicações
Feminino
Seres Humanos
Neoplasias Renais/complicações
Masculino
Mastocitose/complicações
Feocromocitoma/complicações
Neoplasias da Glândula Tireoide/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170816
[St] Status:MEDLINE


  3 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28386644
[Au] Autor:Altmüller J; Haenisch B; Kawalia A; Menzen M; Nöthen MM; Fier H; Molderings GJ
[Ad] Endereço:Cologne Center for Genomics, University of Cologne, D-50931, Cologne, Germany.
[Ti] Título:Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing.
[So] Source:Immunogenetics;69(6):359-369, 2017 Jun.
[Is] ISSN:1432-1211
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mast cell activation syndrome (MCAS) and systemic mastocytosis (SM) are two clinical systemic mast cell activation disease variants. Few studies to date have investigated the genetic basis of MCAS. The present study had two aims. First, to investigate whether peripheral blood leukocytes from MCAS patients also harbor somatic mutations in genes implicated in SM using next-generation sequencing (NGS) technology and a relatively large MCAS cohort. We also addressed the question, whether some of the previously as somatic reported mutations are indeed germline mutations. Second, to identify germline mutations of relevance to MCAS pathogenesis. Here, mutation frequency in the present MCAS cohort was compared to that in public- and in-house databases in the case of frequent variants, and co-segregation was investigated in multiply affected families in the case of rare variants (allele frequency < 1%). MCAS diagnoses were assigned according to current criteria. Twenty five candidate genes were selected on the basis of published findings for SM. NGS was performed using a 76kbp custom designed Agilent SureSelect Target Enrichment and an Illumina Hiseq2000 2x100bp sequencing run. NGS revealed 67 germline mutations. No somatic mutations were detected. None of the germline mutations showed unequivocal association with MCAS. Failure to detect somatic mutations was probably attributable to the dilution of mutated mast cell DNA in normal leukocyte DNA. The present exploratory association findings suggest that some of the detected germline mutations may be functionally relevant and explain familial aggregation. Independent replication studies are therefore warranted.
[Mh] Termos MeSH primário: Leucócitos/metabolismo
Mastocitose/genética
Mutação
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Alelos
Substituição de Aminoácidos
Biomarcadores
Análise Mutacional de DNA
Feminino
Frequência do Gene
Estudo de Associação Genômica Ampla
Genômica/métodos
Mutação em Linhagem Germinativa
Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Masculino
Mastocitose/diagnóstico
Meia-Idade
Linhagem
Fenótipo
Polimorfismo de Nucleotídeo Único
Síndrome
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1007/s00251-017-0981-y


  4 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28332308
[Au] Autor:Ueshima C; Kataoka TR; Takei Y; Hirata M; Sugimoto A; Hirokawa M; Okayama Y; Blumberg RS; Haga H
[Ad] Endereço:Department of Diagnostic Pathology, Kyoto University, Kyoto, Japan.
[Ti] Título:CEACAM1 long isoform has opposite effects on the growth of human mastocytosis and medullary thyroid carcinoma cells.
[So] Source:Cancer Med;6(4):845-856, 2017 Apr.
[Is] ISSN:2045-7634
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in a number of tumor cell types. The immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing isoforms of this molecule which possess a long cytoplasmic tail (CEACAM1-L) generally play inhibitory roles in cell function by interacting with Src homology 2 domain-containing tyrosine phosphatase (SHP)-1 and/or SHP-2. Src family kinases (SFKs) are also known to bind to and phosphorylate CEACAM1-L isoforms. Here, we report that CEACAM1 was uniquely expressed at high levels in both human neoplastic mast cells (mastocytosis) and medullary thyroid carcinoma cell (MTC) lines, when compared with their expression in nonneoplastic mast cells or nonneoplastic C cells. This expression was mainly derived from CEACAM1-L isoforms based upon assessment of CEACAM1 mRNA expression. CEACAM1 knockdown upregulated cell growth of HMC1.2 cells harboring KIT mutations detected in clinical mastocytosis, whereas downregulated the growth of TT cells harboring RET mutations detected in clinical MTCs. Immunoblotting, ELISA and immunoprecipitaion analysis showed that activated SHP-1 is preferentially associated with CEACAM1 in HMC1.2 cells harboring KIT mutations, whereas Src family kinases (SFKs) are preferentially associated with CEACAM1 in TT cells harboring RET mutations. These studies suggest that the dominantly interacting proteins SHP1 or SFK determine whether CEACAM1-L displays a positive or negative role in tumor cells.
[Mh] Termos MeSH primário: Antígenos CD/genética
Antígenos CD/metabolismo
Carcinoma Neuroendócrino/metabolismo
Moléculas de Adesão Celular/genética
Moléculas de Adesão Celular/metabolismo
Mastocitose/metabolismo
Neoplasias da Glândula Tireoide/metabolismo
Quinases da Família src/metabolismo
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Linhagem Celular Tumoral
Criança
Pré-Escolar
Feminino
Regulação Neoplásica da Expressão Gênica
Células HT29
Seres Humanos
Lactente
Recém-Nascido
Células Jurkat
Células K562
Masculino
Meia-Idade
Isoformas de Proteínas/metabolismo
Proteína Tirosina Fosfatase não Receptora Tipo 6
Regulação para Cima
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD); 0 (CD66 antigens); 0 (Cell Adhesion Molecules); 0 (Protein Isoforms); EC 2.7.10.2 (src-Family Kinases); EC 3.1.3.48 (PTPN6 protein, human); EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 6)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.1002/cam4.1050


  5 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262205
[Au] Autor:Afrin LB; Self S; Menk J; Lazarchick J
[Ad] Endereço:Division of Hematology, Oncology and Transplantation, University of Minnesota (UMN), Minneapolis, Minnesota. Electronic address: afrinl@umn.edu.
[Ti] Título:Characterization of Mast Cell Activation Syndrome.
[So] Source:Am J Med Sci;353(3):207-215, 2017 Mar.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mast cell activation syndrome (MCAS), a recently recognized nonneoplastic mast cell disease driving chronic multisystem inflammation and allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population. METHOD: Demographics, comorbidities, symptoms, family histories, physical examination and laboratory findings were reviewed in 298 retrospective and 115 prospective patients with MCAS. Blood samples from prospective subjects were examined by flow cytometry for clonal mast cell disease and tested for cytokines potentially driving the monocytosis frequent in MCAS. RESULTS: Demographically, white females dominated. Median ages at symptom onset and diagnosis were 9 and 49 years, respectively (range: 0-88 and 16-92, respectively) and median time from symptom onset to diagnosis was 30 years (range: 1-85). Median numbers of comorbidities, symptoms, and family medical issues were 11, 20, and 4, respectively (range: 1-66, 2-84, and 0-33, respectively). Gastroesophageal reflux, fatigue and dermatographism were the most common comorbidity, symptom and examination finding. Abnormalities in routine laboratories were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D , histamine and chromogranin A. Flow cytometric and cytokine assessments were unhelpful. CONCLUSIONS: Our study highlights MCAS׳s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects.
[Mh] Termos MeSH primário: Mastocitose/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores/sangue
Criança
Pré-Escolar
Cromogranina A/sangue
Feminino
Heparina/sangue
Histamina/sangue
Seres Humanos
Lactente
Recém-Nascido
Masculino
Mastocitose/diagnóstico
Meia-Idade
Estudos Prospectivos
Prostaglandina D2/sangue
Estudos Retrospectivos
Síndrome
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chromogranin A); 820484N8I3 (Histamine); 9005-49-6 (Heparin); RXY07S6CZ2 (Prostaglandin D2)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE


  6 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28254862
[Au] Autor:Valent P; Akin C; Hartmann K; Nilsson G; Reiter A; Hermine O; Sotlar K; Sperr WR; Escribano L; George TI; Kluin-Nelemans HC; Ustun C; Triggiani M; Brockow K; Gotlib J; Orfao A; Schwartz LB; Broesby-Olsen S; Bindslev-Jensen C; Kovanen PT; Galli SJ; Austen KF; Arber DA; Horny HP; Arock M; Metcalfe DD
[Ad] Endereço:Department of Medicine I, Division of Hematology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria. peter.valent@meduniwien.ac.at.
[Ti] Título:Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.
[So] Source:Cancer Res;77(6):1261-1270, 2017 Mar 15.
[Is] ISSN:1538-7445
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced systemic mastocytosis. .
[Mh] Termos MeSH primário: Mastocitose/classificação
Mastocitose/terapia
[Mh] Termos MeSH secundário: Progressão da Doença
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1158/0008-5472.CAN-16-2234


  7 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28248186
[Au] Autor:Vincenti S; Findji F
[Ad] Endereço:VRCC Veterinary Referrals, Laindon, United Kingdom.
[Ti] Título:Influence of treatment on the outcome of dogs with incompletely excised grade-2 mast cell tumors.
[Ti] Título:Einfluss der Behandlung auf das Ergebnis von Hunden mit unvollständing entfernten Grad-2 Mastzelltumoren..
[So] Source:Schweiz Arch Tierheilkd;159(3):171-177, 2017 Mar.
[Is] ISSN:0036-7281
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In this study we compared the outcomes of dogs with incompletely-excised grade-2 mast cell tumors (incompletely- excised grade-2 MCTs) either adjuvantly treated or not. Dogs with a grade-2 mast cell tumour (MCT) excised either incompletely or with narrow (.
[Mh] Termos MeSH primário: Doenças do Cão/terapia
Mastocitose/veterinária
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/uso terapêutico
Terapia Combinada
Cães
Seguimentos
Lomustina/uso terapêutico
Mastocitose/mortalidade
Mastocitose/terapia
Reoperação
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 7BRF0Z81KG (Lomustine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.17236/sat00109


  8 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28234049
[Au] Autor:Calabria CW; Hauswirth DW; Rank M; Sher L; Larenas-Linnemann D
[Ti] Título:American Academy of Asthma, Allergy & Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children.
[So] Source:Allergy Asthma Proc;38(2):121-129, 2017 Mar 01.
[Is] ISSN:1539-6304
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Few data exist regarding the use of venom immunotherapy (VIT) in specific high-risk chronic medical conditions and pregnancy, and in young children. METHODS: A Web-based survey was sent to American Academy of Asthma Allergy & Immunology members to explore their VIT experience in potential high-risk medical conditions and pregnancy, and in young children. Major problems were defined as "activation of underlying disease and/or VIT not well tolerated (systemic adverse events) and/or VIT discontinued for medical reasons." Results were expressed descriptively. RESULTS: A total of 697 of 5123 surveys (14%) were completed: 87% of the respondents were based in the United States, and 28% worked in an academic setting. Most respondents (71%) believed that pregnancy was a contraindication for starting VIT. Most were comfortable continuing VIT (51%) if the woman became pregnant after starting therapy. Of the allergists who treated children, many would give VIT down to age 5 years (42%) or younger, ages 1-4 years (35%). The following list is of the specific medical condition, the number of allergists who used VIT in patients with this condition, and the percentage who reported major problems: severe asthma, 212 (4.2%); hypertension, 287 (1.1%); coronary artery disease, 222 (3.6%); arrhythmias, 136 (3.4%); cerebrovascular disease, 104 (5.1%); cancer in remission, 166 (0%); cancer stable but still under treatment, 44 (7.2%); a history of bone marrow transplantation, 15 (4.9%); a history of solid organ transplantation, 29 (3.6%); human immunodeficiency virus, 53 (1.4%); acquired immunodeficiency syndrome, 24 (6.2%); stable autoimmune disease, 164 (2.8%); mastocytosis, 66 (18.4%); elevated serum tryptase, 101 (10.8%); immunodeficiency 59 (2.5%). CONCLUSION: Many allergists were comfortable using VIT in young children and continuing but not starting pregnant women on VIT. VIT was commonly used in patients with hypertension, coronary artery disease, arrhythmias, cancer in remission, and stable autoimmune disease. Major problems were most frequently reported in use with mastocytosis, elevated tryptase, and cancer still under treatment.
[Mh] Termos MeSH primário: Anafilaxia/prevenção & controle
Venenos de Artrópodes/uso terapêutico
Atitude do Pessoal de Saúde
Dessensibilização Imunológica/métodos
Hipersensibilidade Imediata/tratamento farmacológico
Padrões de Prática Médica
Complicações na Gravidez/tratamento farmacológico
[Mh] Termos MeSH secundário: Síndrome de Imunodeficiência Adquirida/epidemiologia
Adolescente
Adulto
Fatores Etários
Alergia e Imunologia
Animais
Venenos de Artrópodes/imunologia
Asma/epidemiologia
Doenças Autoimunes/epidemiologia
Transplante de Medula Óssea
Transtornos Cerebrovasculares/epidemiologia
Criança
Pré-Escolar
Doença Crônica
Comorbidade
Doença da Artéria Coronariana/epidemiologia
Feminino
Infecções por HIV/epidemiologia
Seres Humanos
Himenópteros
Hipersensibilidade Imediata/epidemiologia
Hipertensão/epidemiologia
Lactente
Mordeduras e Picadas de Insetos/imunologia
Masculino
Mastocitose/epidemiologia
Neoplasias/epidemiologia
Transplante de Órgãos
Gravidez
Complicações na Gravidez/epidemiologia
Pré-Medicação/utilização
Sociedades Médicas
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Arthropod Venoms)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.2500/aap.2017.38.4024


  9 / 1349 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28185248
[Au] Autor:Bramhall M; Zaph C
[Ad] Endereço:Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
[Ti] Título:Mastering gut permeability: New roles for old friends.
[So] Source:Eur J Immunol;47(2):236-239, 2017 02.
[Is] ISSN:1521-4141
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Mast cells are innate immune cells that respond rapidly to infection in barrier tissues such as the skin and intestinal mucosa. Expulsion of parasitic worms in the gut involves a robust type 2 host response, and an acute mastocytosis is often generated at the site of infection. However, the role of mast cells in resistance to worm infections appears to be parasite specific. Mast cells are also involved in tissue repair, but the long-term contribution of mast cell activation after worm expulsion has not been definitively studied. In this issue of European Journal of Immunology, Sorobetea et al. [Eur. J. Immunol. 2017. 47: 257-268] demonstrate that activated mast cells persist in the large intestinal lamina propria and intraepithelial compartment long after worm expulsion, resulting in continued local and systemic presence of the mast cell protease mast cell protease 1 (MCPt-1) and enhanced intestinal permeability. In this commentary, we discuss these findings in the wider context of mast cell function in health and disease.
[Mh] Termos MeSH primário: Amigos
Mastocitose/imunologia
[Mh] Termos MeSH secundário: Quimases
Seres Humanos
Mucosa Intestinal/imunologia
Intestinos/imunologia
Mastócitos/citologia
Permeabilidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
EC 3.4.21.39 (Chymases)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1002/eji.201646842


  10 / 1349 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28135563
[Au] Autor:Metcalfe DD; Mekori YA
[Ad] Endereço:Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892; email: dmetcalfe@niaid.nih.gov.
[Ti] Título:Pathogenesis and Pathology of Mastocytosis.
[So] Source:Annu Rev Pathol;12:487-514, 2017 Jan 24.
[Is] ISSN:1553-4014
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Systemic mastocytosis is a clonal disorder of mast cells that may variably present with characteristic skin lesions, episodes of mast cell mediator release, and disturbances of hematopoiesis. No curative therapy presently exists. Conventional management has relied on agents that antagonize mediators released by mast cells, inhibit mediator secretion, or modulate mast cell proliferation. Recent advances in the molecular understanding of the pathophysiology of systemic mastocytosis have provided new therapeutic considerations, including new and novel tyrosine kinase inhibitors.
[Mh] Termos MeSH primário: Mastócitos/patologia
Mastocitose/patologia
[Mh] Termos MeSH secundário: Animais
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170131
[St] Status:MEDLINE
[do] DOI:10.1146/annurev-pathol-052016-100312



página 1 de 135 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde